26th week of 2012 patent applcation highlights part 57 |
Patent application number | Title | Published |
20120165289 | TREATMENT - The invention provides composition comprising a therapeutically effective amount of a soluble fibre derivable from fruit of the | 2012-06-28 |
20120165290 | GLUCOOLIGOSACCHARIDES COMPRISING (ALPHA 1->4) AND (ALPHA 1->6) GLYCOSIDIC BONDS, USE THEREOF, AND METHODS FOR PROVIDING THEM - The invention relates to the field of poly- and oligosaccharides and their nutritional effects. In particular, it relates to the application of α-glucanotransferases in methods for preparing dietary fibers, including prebiotic oligosaccharides, and to novel oligosaccharides obtainable thereby. Provided is a method for producing a mixture of gluco-oligosaccharides having one or more consecutive (α1→6) glucosidic linkages and one or more consecutive (α1→4) glucosidic linkages, comprising contacting a poly- and/or oligosaccharide substrate comprising at least two (α1→4) linked D-glucose units with an ?-glucanotransferase capable of cleaving (α1→4) glucosidic linkages and making new (α1→4) and (α1→6) glucosidic linkages. Also provided are (isolated) gluco-oligosaccharides obtainable thereby, and their application in nutritional and cosmetic compositions. | 2012-06-28 |
20120165291 | ACIDIC COMPOSITION FOR EXTERNAL USE AND AGENT FOR ACCELERATING INFILTRATION OF COSMETIC PREPARATION, HAIR-GROWING AGENT, AND PREPARATION FOR EXTERNAL USE EACH CONTAINING THE COMPOSITION INTO SKIN OR THE LIKE - An acidic composition for external use which contains an acidic polysaccharide and water as essential ingredients, and an agent for accelerating the penetration into skin or the like of a cosmetic preparation, hair-growing agent or preparation for external use, each containing the composition. The composition is easy to manufacture, and shows a stronger cosmetic or therapeutic effects than conventional compositions. | 2012-06-28 |
20120165292 | METHODS FOR TREATMENT OF MULTIPLE MYELOMA USING CYCLOPROPANE CARBOXYLIC ACID {2-(Is)-(3-eTHOXY-4METHOXY-PHENYL)-2-METHANESULFONYL-ETHYL}-3-OXO-2.- 3-DIHYDRO-1H-ISOINDOL-4-YL}-AMIDE - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of a selective cytokine inhibitory drug. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2012-06-28 |
20120165293 | SYNTHESIS OF PROSTANOIDS - The presently disclosed subject matter provides a method of synthesizing prostaglandins and prostaglandin analogs comprising the ring closing metathesis of compounds of Formula (I). Also provided are novel compounds of Formula (I) and Formula (II). In addition to their use as synthetic intermediates in the presently disclosed methods, compounds of Formula (II) can be used as prostaglandin and/or prostaglandin analog prodrugs. | 2012-06-28 |
20120165294 | 4,5-DIHYDRO-OXAZOL-2YL DERIVATIVES - The invention relates to compounds of formula I | 2012-06-28 |
20120165295 | Compounds, Compositions and Methods for Treating Ocular Conditions - The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered. | 2012-06-28 |
20120165296 | BISPHOSPHONATE-PRODRUGS - The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer. | 2012-06-28 |
20120165297 | SYNERGISTIC COMBINATION OF A GLYPHOSATE COMPOUND AND DMITS - A synergistic antimicrobial composition containing a glyphosate compound and diiodomethyl-p-tolylsulfone is provided. Also provided is a method of inhibiting the growth of or controlling the growth of microorganisms in a building material by adding such a synergistic antimicrobial composition. Also provided is a coating composition containing such a synergistic antimicrobial composition, and a dry film made from such a coating composition. | 2012-06-28 |
20120165298 | SULFONAMIDE COMPOUNDS - The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of formula (I): | 2012-06-28 |
20120165299 | COMBINATION MEDICAMENT - A medicament for treating inflammation of human or animal body tissues contains a steroid, typically a corticosteroid, in combination with a non-steroidal anti-inflammatory drug (NSAID), typically a cyclooxygenase (COX-1 or COX-2) inhibitor. The medicament is of a particular effectiveness in treating inflammation of and around the eyes, whether caused by infection, irritation or surgery. Further medicaments combine an NSAID with antihistamines or with mast cell stabilisers. The medicaments are particularly effective in topically-applicable form, although other forms of application should also show benefits. | 2012-06-28 |
20120165300 | DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X | 2012-06-28 |
20120165301 | BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS - The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog. The pharmaceutical compositions are useful for treating medical disorders, such as epidermal hyperplasia. | 2012-06-28 |
20120165302 | ANTIFUNGAL FORMULATIONS - A topical composition and the method using the composition, which contains an antifungal agent and a low potency anti-inflammatory steroid which is safe and effective such as desonide or its derivative. The low potency steroid agent does not cause side effects such as skin atrophy, striae and hypopigmentation. The composition can be formulated in a dosage form such as a cream, ointment, gel, lotion, foam, powder, aerosol, spray, shampoo, or liquid solution. The composition can be used to treat a fungal disease such as tinea pedis, tinea capitis, tinea corporis, tinea versicolor, tinea cruris, and candidiasis as well as intertriginous dermatitis complicated by candidiasis. | 2012-06-28 |
20120165303 | TRIAZOLYL PHENYL BENZENESULFONAMIDES - Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists. | 2012-06-28 |
20120165304 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them - The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R | 2012-06-28 |
20120165305 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 - The present invention relates to substituted imidazopyridazines and substituted benzimidazoles, as well as pharmaceutical compositions comprising the same, which are FGFR3 inhibitors useful in the treatment of cancer and other diseases. | 2012-06-28 |
20120165306 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES - The present invention provides a compound of Formula (I): | 2012-06-28 |
20120165307 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 2012-06-28 |
20120165308 | USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS - The present invention provides compounds of the formula (I) | 2012-06-28 |
20120165309 | HETERO RING DERIVATIVE | 2012-06-28 |
20120165310 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS - The invention relates to compounds of formula I, | 2012-06-28 |
20120165311 | 1H-THIENO[2,3-C]PYRAZOLE DERIVATIVES USEFUL AS KINASE INHIBITORS - Thieno[2,3-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2012-06-28 |
20120165312 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF - The present invention relates to a serotonin 5-HT | 2012-06-28 |
20120165313 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR). | 2012-06-28 |
20120165314 | SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS - This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis. | 2012-06-28 |
20120165315 | MEPTAZINOL CARBAMATE PRODRUG SALTS - The present invention relates to salts of meptazinol carbamate prodrugs, and to their synthesis and use. | 2012-06-28 |
20120165316 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF - This invention provides compounds of formula (I): | 2012-06-28 |
20120165317 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS - Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in the treatment of autoimmunity, inflammation allergy, asthma, graft rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency. | 2012-06-28 |
20120165318 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK - Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus. | 2012-06-28 |
20120165319 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME - The present invention relates to novel classes of compounds which are inhibitors of interleukin-1β converting enzyme. The ICE inhibitors of this invention are characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against IL-1-, apoptosis-, IGIF-, and IFN-γ-mediated diseases, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, degenerative diseases, and necrotic diseases. This invention also relates to methods for inhibiting ICE activity, for treating interleukin-1-, apoptosis-, IGIF- and IFN-γ-mediated diseases and decreasing IGIF and IFN-γ production using the compounds and compositions of this invention. This invention also relates to methods for preparing N-acylamino compounds. | 2012-06-28 |
20120165320 | NOVEL AZABICYCLOHEXANES - The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. | 2012-06-28 |
20120165321 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 2012-06-28 |
20120165322 | RHO KINASE INHIBITORS - The present invention relates to compounds of formula (I): | 2012-06-28 |
20120165323 | METHOD FOR IMPROVING THE DISSOLUTION PROFILE OF A BIOLOGICALLY ACTIVE MATERIAL - The present invention relates to a method for improving the dissolution profile of a biologically active material comprising the steps of dry milling a solid biologically active material and a millable grinding matrix in a mill comprising a plurality of milling bodies, for a time period sufficient to produce particles of the biologically active material dispersed in an at least partially milled grinding material. | 2012-06-28 |
20120165324 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE - Compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 2012-06-28 |
20120165325 | Stable forms of N-(2,6-Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide - Polymorphic forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide are provided together with a process for the manufacture of said compound. | 2012-06-28 |
20120165326 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO BENZOTHIAZOLES AND 5-FLUORO BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS - The invention relates to novel products of the formula (I) where: (II) is a single or double bond; F is a fluorine atom, Ra is H, HaI, alkoxy, O-cycloalkyl, —O— heterocycloalkyl; —NH-heterocycloalkyl, heteroaryl, phenyl, NHCOalk NHCOcycloalk or NR1 R2; X is S, SO or SO2, A is NH or S; W is H, alkyl, or COR with R being cycloalkyl; alkyl optionally substituted by NR3R4, alkoxy, hydroxy, phenyl, heteroaryl or heterocycloalkyl; alkoxy optionally substituted by NR3R4, i.e. a O—(CH2)n-NR3R4 radical, an O-phenyl or an O—(CH2)n-phenyl radical, with phenyl optionally substituted and n=1 to 4; or the NR1 R2 radical; R1 is H or alk and R2 is H, cycloalkyl or alkyl; R3 and R4 are H, alk, cycloalkyl, heteroaryl or phenyl; R1, R2 and/or R3, R4 form a cycle together with N optionally containing O, S, N and/or NH; heterocycloalkyl, heteroaryl and phenyl and cycles all being optionally substituted; wherein said products can be in any isomer or salt form, and can be used as drugs, in particular as MET inhibitors. | 2012-06-28 |
20120165327 | SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS - The present invention is directed to a compound of Formula (I): | 2012-06-28 |
20120165328 | INHIBITORS OF B LYMPHOCYTE KINASE - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2012-06-28 |
20120165329 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one of Fms protein kinase or Kit protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Fms protein kinases and/or Kit protein kinases, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, myelopreparation for autologous transplantation, transplant rejection, nephritis, nephropathy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastomas, neurofibromatosis, osteolytic bone metastases, and giant cell tumors. | 2012-06-28 |
20120165330 | QUINAZOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS - Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent. | 2012-06-28 |
20120165331 | Di/tri-aza-spiro-C9-C11alkanes - The invention relates to compounds of the formula I | 2012-06-28 |
20120165332 | SULFONAMIDES AND SULFAMIDES AS ZAP-70 INHIBITORS - The invention relates to compounds of formula (I) | 2012-06-28 |
20120165333 | C-MET PROTEIN KINASE INHIBITORS - The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders. | 2012-06-28 |
20120165334 | Indole/Benzimidazole Compounds as mTOR Kinase Inhibitors - The present invention provides compounds that are kinase inhibitors, specifically PIK kinase inhibitors, more specifically, mTOR inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of kinases, specifically PIK kinase inhibitors, more specifically, mTOR such as cancer. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 2012-06-28 |
20120165335 | CDK INHIBITORS - The present invention relates to CDK inhibitors and their use in the treatment of cell proliferative diseases such as cancer. | 2012-06-28 |
20120165336 | Color Change Time Indicator for Packaging System - Disclosed in certain embodiments is a pharmaceutical packaging system comprising: a receptacle comprising an openable seal for accessing the interior of the receptacle; a pharmaceutical dosage form contained in the receptacle; and an activatable color-changing material, wherein upon activation, the material exhibits a visually discernible color change upon the lapsing of a predetermined time period. | 2012-06-28 |
20120165337 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF - The invention relates to compounds of formula (I), where: A is a bond, an oxygen atom, or an | 2012-06-28 |
20120165338 | NEW BIARYL AMIDE DERIVATIVES - The invention provides novel compounds having the general formula (I) | 2012-06-28 |
20120165339 | CYCLOPROPANE DERIVATIVES - A cyclopropane derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof has orexin receptor inhibitory action, and thus, is extremely useful as an agent for preventing or treating sleep disorder or dyssomnia caused by orexin, including insomnia as a typical example: | 2012-06-28 |
20120165340 | PTEN PHOSPHORYLATION-DRIVEN RESISTANCE TO CANCER TREATMENT AND ALTERED PATIENT PROGNOSIS - Indicators that can guide clinical decisions in cancer, particularly posttranslational modification of proteins which result in altered prognosis and differential sensitivity to targeted cancer therapy, are provided. In particular, monitoring of phosphorylation of PTEN may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome. Modulation of PTEN phosphorylation may be utilized to alter sensitivity and outcome in cancer patients. Posttranslational modification of PTEN, particularly phosphorylation, is correlated with resistance to targeted cancer therapy, including EGFR inhibitors, and with reduced survival prognosis. Methods and assays for determining phosphorylation of PTEN, particularly Y240 phosphorylation, are provided. Methods for sensitizing tumors to inhibition and targeted therapy by modulating PTEN phosphorylation are provided. | 2012-06-28 |
20120165341 | THERAPEUTIC AGENT FOR SENILE DEMENTIA - A therapeutic/preventive agent for cognitive dysfunctions, which comprises as an active ingredient an imide derivative of the following formula [1]: | 2012-06-28 |
20120165342 | Methods of Reducing Risk of Infection from Pathogens - Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment. | 2012-06-28 |
20120165343 | Glucagon Receptor Modulators - The present invention provides a compound of Formula (I) | 2012-06-28 |
20120165344 | Compounds for the Treatment of Hepatitis C - The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2012-06-28 |
20120165345 | Heterocyclic compounds as pesticides - The present application relates to novel heterocyclic compounds, to the use thereof for controlling animal pests, which include arthropods and especially insects, and to processes for preparing the novel compounds. | 2012-06-28 |
20120165346 | Compounds and their use as BACE inhibitors - The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. | 2012-06-28 |
20120165347 | Compounds and their use as BACE Inhibitors - The present invention relates to compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. | 2012-06-28 |
20120165348 | Novel compounds - The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation. | 2012-06-28 |
20120165349 | Phenyl-Substituted Pyrazolopyrimidines - The invention relates to novel phenyl-substituted pyrazolopyrimidines, process for their preparation, and their use for producing medicaments for improving perception, concentration, learning and/or memory. | 2012-06-28 |
20120165350 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS - Disclosed is a synthesis suitable for large scale manufacture of an A | 2012-06-28 |
20120165351 | QUINAZOLINE DERIVATIVES - The invention concerns quinazoline derivatives of Formula I | 2012-06-28 |
20120165352 | 6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF - 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their uses as treatment agents especially as protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification. | 2012-06-28 |
20120165353 | NOVEL PHENYLPYRIDINE DERIVATIVE AND MEDICINAL AGENT COMPRISING SAME - Disclosed are: a novel compound which has both an antagonistic activity on an angiotensin II receptor and a PPARγ-activating activity and is therefore useful as a prophylactic and/or therapeutic agent for hypertension, heart diseases, arteriosclerosis, type-2 diabetes, diabetic complications, metabolic syndrome or the like; and a pharmaceutical composition containing the compound. Specifically disclosed are: a compound represented by general formula (I) (wherein the ring A represents a pyridine ring; the ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R | 2012-06-28 |
20120165354 | TREATMENT METHOD - The present invention relates to methods of treating age-related macular degeneration in a patient by administration of pazopanib or pharmaceutically acceptable salts or solvates thereof. | 2012-06-28 |
20120165355 | METHODS AND COMPOSITIONS FOR TREATING CANCERS - This invention provides a combination of antagonists of the hedgehog signaling pathway with a BCR-ABL inhibitor. The combination of the present invention may be used for treating cancers known to be associated with protein tyrosine kinases such as, for example, Src, BCR-ABL and c-kit. | 2012-06-28 |
20120165356 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE - Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions. | 2012-06-28 |
20120165357 | Compositions Containing Berberine or Analogs Thereof for Treating Rosacea or Red Face Related Skin Disorders - The invention pertains to topical pharmaceutical formulations of berberine and its biologically equivalent analogues, such as palmatine and coptisine, for the treatment of rosacea and other red face-related skin disorders. The topical pharmaceutical formulations of this invention contain purified berberine as the primary active drug ingredient at concentrations higher than 0.1%. The invention also pertains to methods of treating rosacea and other red face related skin disorders, such as steroid-induced rosacea-like dermatitis, comprising the administration of topical pharmaceutical formulations that contain berberine or its biologically equivalent analogues, such as palmatine. | 2012-06-28 |
20120165361 | DRUG COATING PROVIDING HIGH DRUG LOADING AND METHODS FOR PROVIDING THE SAME - The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention. | 2012-06-28 |
20120165362 | Androgen receptor modulator compounds and methods - Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors, and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions. | 2012-06-28 |
20120165363 | Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders - Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine. | 2012-06-28 |
20120165365 | Compositions and Methods for Treating Cancer - The present invention embraces bis-acridine and bis-quinoline intercalators having a bis(4-aminophenyl)ether tether, and diglycolate salts thereof, for selectively decreasing colon cancer and glial cell proliferation and preventing or treating colon cancers and gliomas. | 2012-06-28 |
20120165366 | COMPOUNDS AND USES THEREOF - N-[3-(4-Cyano-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, N-[3-(4-ethynyl-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluoro-phenyl]-4-trifluoromethyl-benzenesulfonamide, and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including pain and polycystic kidney disease. | 2012-06-28 |
20120165367 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2012-06-28 |
20120165368 | PYRAZOLOPYRIDINE KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2012-06-28 |
20120165369 | 3-SUBSTITUTED QUINOLINIUM AND 7H-INDOLO[2,3-c]QUINOLINIUM SALTS AS NEW ANTIINFECTIVES - The present invention relates to quinolinium antiinfective agents in which the qunolinium nucleus is fused to an indole ring or the qunolinium nucleus is linked to a cyclic structure through an opened indole or a benzothiophene or benzofuran ring. The compound is further substituted with various substituent groups. | 2012-06-28 |
20120165370 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS - Quinoline derivatives showing anticancer activities against cancer cell lines of hepatocellular carcinoma (Hep3B), lung carcinoma (A549), esophageal squamous cell carcinoma (HKESC-1, HKESC-4 and KYSE150). The quinoline derivatives have a backbone structure of the following formulas: | 2012-06-28 |
20120165371 | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS - The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans. | 2012-06-28 |
20120165372 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE- -3-CARBOXAMIDE - Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide are described herein, including crystalline forms thereof. | 2012-06-28 |
20120165373 | Method of Treating Skin with microRNA Modulators - Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ active agents that suppress or down-regulate microRNA expression in dermal fibroblast, resulting in enhanced production of collagen, elastin and/or fibrillin in the skin. Also provided are methods for screening for activity against specific microRNAs and the methods of using active agents identified by the screening protocol in the treatment of skin. | 2012-06-28 |
20120165374 | AGENTS FOR CONTROLLING PLANT PESTS - The present invention relates to compositions for controlling plant pests containing the compound of the formula (I) | 2012-06-28 |
20120165375 | Urea Glucokinase Activators - This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a process for preparing such. | 2012-06-28 |
20120165376 | STABILIZED MICROBICIDAL COMPOSITION - A microbicidal composition having at least four components. The first component is 2-25 wt % of 2,2-dibromo-3-nitrilopropionamide. The second component is 2-30 wt % water. The third component is 5-30 wt % of an aliphatic compound having 2-6 hydroxyl groups. The fourth component is 20-70 wt % of a glycol solvent. | 2012-06-28 |
20120165377 | AGENT FOR REDUCING VISCERAL FAT WEIGHT - An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): | 2012-06-28 |
20120165378 | THIOPHENE-CARBOXAMIDES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, or disorders. The invention also relates to processes for preparing compounds of the inventions. | 2012-06-28 |
20120165379 | ALLANTOIN-CONTAINING SKIN CREAM - An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant. | 2012-06-28 |
20120165380 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS - Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an α-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic. | 2012-06-28 |
20120165381 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS - The invention is directed to compounds having the formula: | 2012-06-28 |
20120165382 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE - The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula | 2012-06-28 |
20120165383 | INFLAMMATORY EYE DISEASE - The present invention provides methods, kits and compositions for treating uveitis in a subject using Hsp90 inhibitors. | 2012-06-28 |
20120165384 | INHIBITION OF HISTONE ACETYLTRANSFERASES BY CTK7A AND METHODS THEREOF - The present disclosure relates to a method for inhibiting histone acetyltransferases by derivative of curcumin, particularly CTK7A. The present disclosure also relates to identification of induction of autoacetylation of p300 and its inhibition by CTK7A. The disclosure also relates to induction of NPM1 and GAPDH overexpression and corresponding hyperacetylation of histone and methods thereof. | 2012-06-28 |
20120165385 | Novel Compounds And Compositions Thereof - The invention relates to novel compounds containing a carboxylic acid head group. The invention further provides compositions containing the novel compounds, a particulate solid and an organic medium or water. | 2012-06-28 |
20120165386 | STABLE ORAL PHARMACEUTIAL COMPOSITION OF ATORVASTATIN - The present invention relates to a stable oral pharmaceutical composition comprising atorvastatin or a pharmaceutically acceptable salt thereof and an alkalizing agent, wherein the buffering capacity of the composition is between 2 to 5. | 2012-06-28 |
20120165387 | General composition framework for ligand-controlled RNA regulatory systems - The invention provides an improved design for the construction of extensible nucleic acid-based, ligand-controlled regulatory systems, and the nucleic acid regulatory systems resulting therefrom. The invention contemplates improving the design of the switches (ligand-controlled regulatory systems) through the design of an information transmission domain (ITD). The improved ITD eliminates free-floating ends of the switching and the competing strands, and localizes competitive hybridization events to a contiguous strand of competing and switching strands in a strand-displacement mechanism-based switch, thereby improving the kinetics of strand-displacement. The improved regulatory systems have many uses in various biological systems, including gene expression control or ligand-concentration sensing. | 2012-06-28 |
20120165388 | FATTY ACID BINDING PROTEINS AS DRUG TARGETS FOR ENDOCANNABINOIDS - The invention provides a method of modulating the level of an endocannabinoid in a subject in need thereof comprising administering an effective amount of an agent that inhibits the interaction of the endocannabinoid with an intracellular fatty acid binding protein (FABP). The invention also provides a method of identifying an agent for modulating the level of an endo cannabinoid in a subject comprising testing the agent for its ability to modulate binding of the endocannabinoid with an intracellular FABP. The invention also provides a method of identifying an agent for modulating the level of an endocannabinoid in a subject comprising testing the agent for its ability to modulate expression of an intracellular FABP. The invention also provides a method of identifying an agent for treatment of a neurological disorder comprising testing the agent for its ability to modulate the interaction of an endocannabinoid with an intracellular FABP. The invention also relates to modulation of levels of fatty acid amides for treatment or amelioration of diseases or disorders by modulating binding of the fatty acid amides to fatty acid binding proteins. In one embodiment, the fatty acid binding protein is one or more of FABP3, FABP5, and FABP7. In one embodiment, the level of an endocannabinoid is modulated. | 2012-06-28 |
20120165389 | ANTISENSE OLIGONUCLEOTIDES THAT TARGET A CRYPTIC SPLICE SITE IN USH1C AS A THERAPEUTIC FOR USHER SYNDROME - The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript. | 2012-06-28 |
20120165390 | Compositions and Methods for Therapy and Diagnosis of Cancer - The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. | 2012-06-28 |
20120165391 | USE OF INHIBITORS OF ZDHHC2 ACTIVITY FOR MODULATION OF ADIPOGENESIS - The present invention concerns Zdhhc2, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Zdhhc2 activity in adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Zdhhc2 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders. | 2012-06-28 |
20120165392 | Identification of Micro-RNAS Involved in Post-Myocardial Infarction Remodeling and Heart Failure - The present invention relates to the identification of miRNAs that are involved in heart failure and the process of post-myocardial infarction remodeling in heart tissue. Modulation of these identified miRNAs as a treatment for myocardial infarction, cardiac remodelling, and heart failure is described. | 2012-06-28 |